Reversibility of platelet thrombosis in vivo

Quantitative analysis in porcine carotid arteries

Waldemar Wysokinski, Robert McBane, James H. Chesebro, Whyte G. Owen

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Reversibility in vivo of acute platelet thrombosis in response to specific anticoagulants is analyzed with thrombi that develop in segments (1 cm) of porcine carotid arteries externally crushed with a hemostat. Most thrombi fill the lumens of the injured segments (ca. 1 cm × 3 mm, 1 × w) within 30 min and comprise masses of platelets interpenetrated with neutrophil-lined seepage channels of blood. Continuous quantitative assay of thrombus mass is provided by a gamma detector placed over the injured segments to collect counts from 111In-labeled platelets. Thrombi established 30 min after injury, otherwise stable for 6 h, clear during 30-60 min of continuous infusion of either hirudin, tick anticoagulant or activated porcine protein C, or intermittent activation of endogenous protein C with a latent thrombin reagent. Anticoagulant dose-dependence of thrombus clearance is established for hirudin between 0.01 and 1.0 mg/kg/min. Thrombi become progressively refractory to hirudin between 0.5 and 6 h after injury. Neither heparin nor low-molecular-weight heparin in full (clinical) anticoagulant doses yield significant dethrombosis. It is concluded that, within time limits, controlled thrombin generation in platelet thrombi maintains platelet cohesion without catalyzing irreversible platelet aggregation or clotting of fibrinogen.

Original languageEnglish (US)
Pages (from-to)1108-1113
Number of pages6
JournalThrombosis and Haemostasis
Volume76
Issue number6
StatePublished - Dec 1996

Fingerprint

Carotid Arteries
Thrombosis
Swine
Blood Platelets
Hirudins
Anticoagulants
Protein C
Thrombin
Low Molecular Weight Heparin
Wounds and Injuries
Ticks
Platelet Aggregation
Fibrinogen
Heparin
Neutrophils

ASJC Scopus subject areas

  • Hematology

Cite this

Wysokinski, W., McBane, R., Chesebro, J. H., & Owen, W. G. (1996). Reversibility of platelet thrombosis in vivo: Quantitative analysis in porcine carotid arteries. Thrombosis and Haemostasis, 76(6), 1108-1113.

Reversibility of platelet thrombosis in vivo : Quantitative analysis in porcine carotid arteries. / Wysokinski, Waldemar; McBane, Robert; Chesebro, James H.; Owen, Whyte G.

In: Thrombosis and Haemostasis, Vol. 76, No. 6, 12.1996, p. 1108-1113.

Research output: Contribution to journalArticle

Wysokinski, W, McBane, R, Chesebro, JH & Owen, WG 1996, 'Reversibility of platelet thrombosis in vivo: Quantitative analysis in porcine carotid arteries', Thrombosis and Haemostasis, vol. 76, no. 6, pp. 1108-1113.
Wysokinski, Waldemar ; McBane, Robert ; Chesebro, James H. ; Owen, Whyte G. / Reversibility of platelet thrombosis in vivo : Quantitative analysis in porcine carotid arteries. In: Thrombosis and Haemostasis. 1996 ; Vol. 76, No. 6. pp. 1108-1113.
@article{b0511a52b42d4dc9967a6864dbb4b9c6,
title = "Reversibility of platelet thrombosis in vivo: Quantitative analysis in porcine carotid arteries",
abstract = "Reversibility in vivo of acute platelet thrombosis in response to specific anticoagulants is analyzed with thrombi that develop in segments (1 cm) of porcine carotid arteries externally crushed with a hemostat. Most thrombi fill the lumens of the injured segments (ca. 1 cm × 3 mm, 1 × w) within 30 min and comprise masses of platelets interpenetrated with neutrophil-lined seepage channels of blood. Continuous quantitative assay of thrombus mass is provided by a gamma detector placed over the injured segments to collect counts from 111In-labeled platelets. Thrombi established 30 min after injury, otherwise stable for 6 h, clear during 30-60 min of continuous infusion of either hirudin, tick anticoagulant or activated porcine protein C, or intermittent activation of endogenous protein C with a latent thrombin reagent. Anticoagulant dose-dependence of thrombus clearance is established for hirudin between 0.01 and 1.0 mg/kg/min. Thrombi become progressively refractory to hirudin between 0.5 and 6 h after injury. Neither heparin nor low-molecular-weight heparin in full (clinical) anticoagulant doses yield significant dethrombosis. It is concluded that, within time limits, controlled thrombin generation in platelet thrombi maintains platelet cohesion without catalyzing irreversible platelet aggregation or clotting of fibrinogen.",
author = "Waldemar Wysokinski and Robert McBane and Chesebro, {James H.} and Owen, {Whyte G.}",
year = "1996",
month = "12",
language = "English (US)",
volume = "76",
pages = "1108--1113",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "6",

}

TY - JOUR

T1 - Reversibility of platelet thrombosis in vivo

T2 - Quantitative analysis in porcine carotid arteries

AU - Wysokinski, Waldemar

AU - McBane, Robert

AU - Chesebro, James H.

AU - Owen, Whyte G.

PY - 1996/12

Y1 - 1996/12

N2 - Reversibility in vivo of acute platelet thrombosis in response to specific anticoagulants is analyzed with thrombi that develop in segments (1 cm) of porcine carotid arteries externally crushed with a hemostat. Most thrombi fill the lumens of the injured segments (ca. 1 cm × 3 mm, 1 × w) within 30 min and comprise masses of platelets interpenetrated with neutrophil-lined seepage channels of blood. Continuous quantitative assay of thrombus mass is provided by a gamma detector placed over the injured segments to collect counts from 111In-labeled platelets. Thrombi established 30 min after injury, otherwise stable for 6 h, clear during 30-60 min of continuous infusion of either hirudin, tick anticoagulant or activated porcine protein C, or intermittent activation of endogenous protein C with a latent thrombin reagent. Anticoagulant dose-dependence of thrombus clearance is established for hirudin between 0.01 and 1.0 mg/kg/min. Thrombi become progressively refractory to hirudin between 0.5 and 6 h after injury. Neither heparin nor low-molecular-weight heparin in full (clinical) anticoagulant doses yield significant dethrombosis. It is concluded that, within time limits, controlled thrombin generation in platelet thrombi maintains platelet cohesion without catalyzing irreversible platelet aggregation or clotting of fibrinogen.

AB - Reversibility in vivo of acute platelet thrombosis in response to specific anticoagulants is analyzed with thrombi that develop in segments (1 cm) of porcine carotid arteries externally crushed with a hemostat. Most thrombi fill the lumens of the injured segments (ca. 1 cm × 3 mm, 1 × w) within 30 min and comprise masses of platelets interpenetrated with neutrophil-lined seepage channels of blood. Continuous quantitative assay of thrombus mass is provided by a gamma detector placed over the injured segments to collect counts from 111In-labeled platelets. Thrombi established 30 min after injury, otherwise stable for 6 h, clear during 30-60 min of continuous infusion of either hirudin, tick anticoagulant or activated porcine protein C, or intermittent activation of endogenous protein C with a latent thrombin reagent. Anticoagulant dose-dependence of thrombus clearance is established for hirudin between 0.01 and 1.0 mg/kg/min. Thrombi become progressively refractory to hirudin between 0.5 and 6 h after injury. Neither heparin nor low-molecular-weight heparin in full (clinical) anticoagulant doses yield significant dethrombosis. It is concluded that, within time limits, controlled thrombin generation in platelet thrombi maintains platelet cohesion without catalyzing irreversible platelet aggregation or clotting of fibrinogen.

UR - http://www.scopus.com/inward/record.url?scp=0030456448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030456448&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 1108

EP - 1113

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 6

ER -